Norovirus Treatment Reliant on Analgesic Drugs Discovery: Fact.MR

04 Mar 2021
www.biospace.com
Vaccine
Growing mortality rates arising out of surging gastrointestinal infections, including diarrhea, is prompting governments to fund drug and vaccine development programs to mitigate this global burden Analgesic norovirus treatment drugs will continue to witness growing preference among healthcare providers, according to latest findings by consulting firm Fact.MR. In a new study on global norovirus treatment market, sales are likely to witness gains in 2021 as effective gastrointestinal treatment becomes key focus area. The report opines an optimistic outlook on the norovirus treatment market for the future. The Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders study of 2020 estimates that over 40% people globally suffer from functional gastrointestinal disorders (FGIDs). Furthermore, nearly 1.6 million people succumbed to diarrheal diseases in 2017, with maximum mortalities occurring in Sub-Saharan Africa and India respectively. Acknowledging this burden, healthcare providers have incorporated numerous advanced treatment approaches, thus stimulating key drug development projects. For instance, Lumen Bioscience initiated clinical trials in 2018 to develop a potential drug candidate to address this growing burden of norovirus infections. While results have currently proven to be inconclusive, efforts are underway to dole out a potential treatment alternative in the upcoming financial year. Likewise, Takeda Pharmaceuticals acquired LigoCyte to develop a pipeline of virus-like particle (VLP)-based vaccines for gastrointestinal and respiratory infections, including norovirus infections. “Manufacturers are accelerating their research and development capacities to dole out potential drug and vaccine candidates in the future. Current dearth of any direct approach to eradicating the virus is widening expansion prospects, thereby widening the revenue prospects for key players operating within the market,” says the Fact.MR analyst. Request a report sample to gain comprehensive insights at Key Takeaways Analgesic norovirus treatment drugs to acquire surging popularity, attributed to easy over-the-counter availability Retail pharmacies will record highest sales of norovirus treatment medicines US sales will account for significant share of global reveues Breakthroughs in treatment procedures to accelerate growth prospects across the UK Germany and France to emerge as highly lucrative markets, fueled by increasing investments in stomach infection treatments India and China to generate potential revenue ecosystems in the forthcoming decade Prominent Drivers Increased consumption of contaminated food and water is increasing norovirus infection incidences, bolstering treatment prospects Manufacturers are finding increased opportunities in development of antiviral fluids Fast-track governmental approvals of key drug candidates to bolster future sales of norovirus treatment drugs Key Restraints Increased frequency of product recalls amid perceived ineffectiveness to hamper sales Expensive diagnostics for the infection discourages patients across developing economies to desist from seeking treatment, thus limiting penetration Discover more about the ultrasonic scalpels market with figures, data tables and the table of contents. You will also find detailed market segmentation on Competitive Landscape Prominent companies include NIMRAJ CHEM AGROVET, Meda Pharmaceuticals Inc., Mizuno Pharmacies and Valeant Pharmaceuticals International Inc. (Bausch Health). The market is highly fragmented, leading to heightened competition levels. Therefore, a variety of expansion strategies are being deployed by the aforementioned market players. In February 2021, Bausch Health Companies’ Salix Pharmaceuticals announced the opening of the application period for the 2021 Salix Gastrointestinal Health Scholars Program. The program is expected to award 10 outstanding students living with a GI disease a scholarship of up to US$ 10,000 to help them pursue higher education goals. For Critical Insights on this Market, Request for More Info More Insights on the Norovirus Treatment Market In its latest report, Fact.MR offers unbiased analysis of the global norovirus treatment market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (electrolytes, intravenous fluids, antipyretics & analgesics) and end users (hospital pharmacies, online pharmacies & retail pharmacies) across seven major regions (North America, APEJ, Japan, Western Europe, Eastern Europe, Latin America and Middle East & Africa). Explore Fact.MR’s Coverage on the Healthcare Domain Circulating Tumor Cells (CTC) Diagnostics Market: Fact.MR has published a new study to elucidate the potential growth parameters of the Circulating Tumor Cell (CTC) diagnostics market. The study has been authored by a team of seasoned analysts who studied various geopolitical, macro and microeconomics, and sociological factors that can influence the growth of the market in order to reach valuable and reliable conclusions. Viral Antigens Market: Fact.MR recently published a market study on the global market for viral antigens. The study provides detailed assessment on the key market dynamics, including drivers, trends, opportunities, and restraints, as well as detailed information about the viral antigens market structure. High Flow Nasal Cannula Market: Fact.MR’s expansive high flow nasal cannula market report sheds light on the prominent dynamics expected to shape future growth. The study explicates on the prominent drivers, opportunities and trends prevailing across key segments in prominent geographies. Also, information regarding prominent manufacturers has been embedded in the report. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Sudip Saha US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.